Publications
Detailed Information
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baek, Sun Kyung | - |
dc.contributor.author | Jeong, Jae-ho | - |
dc.contributor.author | Jung, Kyunghae | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Kim, Min Hwan | - |
dc.contributor.author | Sohn, Joohyuk | - |
dc.contributor.author | Park, In Hae | - |
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Lee, Dae-Won | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Sim, Sung Hoon | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Hyun Kim, Jee | - |
dc.contributor.author | Shim, Hyun-Jeong | - |
dc.contributor.author | Chae, Yeesoo | - |
dc.contributor.author | Koh, Su-Jin | - |
dc.contributor.author | Lee, Hyorak | - |
dc.contributor.author | Lee, Jieun | - |
dc.contributor.author | Byun, Jae-Ho | - |
dc.contributor.author | Seol, Youngmi | - |
dc.contributor.author | Lee, Eun Mi | - |
dc.contributor.author | Jee, Hee-Jung | - |
dc.contributor.author | An, Hyonggin | - |
dc.contributor.author | Park, Eun Byeol | - |
dc.contributor.author | Suh, Young Ju | - |
dc.contributor.author | Lee, Kyoung Eun | - |
dc.contributor.author | Park, Yeon Hee | - |
dc.date.accessioned | 2024-02-16T07:40:51Z | - |
dc.date.available | 2024-02-16T07:40:51Z | - |
dc.date.created | 2024-02-15 | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | Therapeutic Advances in Medical Oncology, Vol.16, pp.1-15 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | https://hdl.handle.net/10371/198999 | - |
dc.description.abstract | Purpose: This study aimed to investigate clinical practices and factors related to the outcomes of T-DM1 use in patients with HER2-positive metastatic breast cancer (mBC). Methods: We included patients with HER2-positive mBC who received T-DM1 as a palliative therapy between August 2017 and December 2018. The safety and outcomes of T-DM1, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), were evaluated. A Cox proportional hazards model was used to estimate the hazard ratio and 95% confidence interval (CI) for mortality or progression to HER2-positive mBC. Results: In total, 824 patients were enrolled during the study period. The mean age of patients was 58 years, and 516 (62.6%) patients relapsed after curative treatment. Excluding a history of endocrine therapy, 341 (41.4%) patients previously received none or first-line chemotherapy, 179 (21.7%) received second-line therapy, and 303 (36.9%) received third-or later-line chemotherapy before T-DM1 therapy. During a median follow-up of 16.8 months, the ORR was 35%, the median PFS was 6.6 months, and the median OS was not reached. The clinical factors associated with the hazard of progression were age (<65 years), poor performance status (>2), advanced line of palliative chemotherapy (>2), prior pertuzumab use, and treatment duration of palliative trastuzumab (<10 months). Common grade 3-4 adverse events were thrombocytopenia (n = 107, 13.2%), neutropenia (n = 23, 2.8%), anemia (n = 21, 2.6%), and elevated liver enzyme (n = 20, 2.5%). Hypokalemia (<= 3.0 mmol/L) and any-grade bleeding events occurred in 25 (3.1%) and 94 (22.6%) patients, respectively. Conclusion: This is the first nationwide real-world study of T-DM1 use in patients with HER2-positive mBC in Korea. The effectiveness and toxicity profiles of T-DM1 in real-world practice were comparable to those in randomized trials. Moreover, patient factors and previous anti-HER2 therapy could predict the outcomes of T-DM1 therapy. | - |
dc.language | 영어 | - |
dc.publisher | SAGE Publications | - |
dc.title | A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) | - |
dc.type | Article | - |
dc.identifier.doi | 10.1177/17588359231225029 | - |
dc.citation.journaltitle | Therapeutic Advances in Medical Oncology | - |
dc.identifier.wosid | 001156764600001 | - |
dc.identifier.scopusid | 2-s2.0-85183673440 | - |
dc.citation.endpage | 15 | - |
dc.citation.startpage | 1 | - |
dc.citation.volume | 16 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Dae-Won | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ANTIBODY-DRUG CONJUGATE | - |
dc.subject.keywordPlus | TRASTUZUMAB EMTANSINE | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | PHYSICIANS CHOICE | - |
dc.subject.keywordPlus | DERUXTECAN | - |
dc.subject.keywordPlus | PERTUZUMAB | - |
dc.subject.keywordPlus | LAPATINIB | - |
dc.subject.keywordPlus | DS-8201A | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordAuthor | HER2 positive | - |
dc.subject.keywordAuthor | metastatic breast cancer | - |
dc.subject.keywordAuthor | real-world data | - |
dc.subject.keywordAuthor | T-DM1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.